Emergent BioSolutions Receives $44 Million CDC Contract to Further Advance Vaccinia Immune Globulin Intravenous Program

(Released 13 August 2015) Gaithersburg, MD - Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Centers for Disease Control and Prevention(CDC) has exercised options under contract 200-2012-52242 for the supply of Vaccinia Immune Globulin (VIGIV) into the U.S. Strategic National Stockpile. VIGIV is a therapeutic licensed by the U.S. Food and Drug Administration (FDA) for the treatment of complications due to smallpox vaccination. The contract options, valued at $44 million over two years, will require Emergent to collect plasma for future manufacturing in addition to current collection requirements, conduct manufacturing runs, and conduct additional activities in support of maintaining the FDA licensure of VIGIV.

"Emergent is proud to support the U.S. government's implementation of its long-term stockpiling strategy. Thirteen years after VIGIV was first delivered to the SNS, VIGIV still remains a critical medical countermeasure in the government's preparedness efforts," said  Adam Havey , executive vice president and president biodefense division of Emergent BioSolutions. "We are pleased that CDC has exercised these contract options and look forward to successfully addressing their requirements."

This contract modification increases the total contract value to approximately $80 million. The scope of the contract, originally awarded to Cangene Corporation, which Emergent acquired in February 2014, was to maintain the ability to manufacture licensed VIGIV, with annual options to conduct additional services to support licensure maintenance activities for the product and to allow for additional manufacturing and plasma collections. VIGIV was first delivered into the SNS in 2002 and was subsequently licensed in the U.S. by FDA in 2005 and in Canada by Health Canada in 2007.

About Emergent BioSolutions Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.